Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349491 · ClinicalTrials.gov registry record · Phase 3
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
A Phase 3 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT01349491: Clinical Trial Phase 3 study, sponsored by University of Oklahoma.
NCT01349491 is a Phase 3 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 10 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01349491, a Phase 3 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with persistent AF who are candidates for electrical cardioversion will be randomized to either placebo or ranolazine after successful electrical cardioversion.
Primary Outcome
To determine if ranolazine is effective in decreasing recurrences of AF in patients with persistent AF successfully treated with electrical cardioversion.
Interventions
- DRUG Matching placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Why NCT01349491 stopped before completion
NCT01349491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT01349491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01349491 about?
NCT01349491 is a clinical study titled "Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion". The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with persistent AF who are candidates for electrical cardioversion will be randomized to either placebo or ranolazine after s...
What is the current status of trial NCT01349491?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2012-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01349491?
The interventions under investigation include: Matching placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01349491?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01349491's enrollment target sits among peer trials
10 1989th of 2000 higher than 9 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia